vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Ispire Technology Inc. (ISPR). Click either name above to swap in a different company.
Ispire Technology Inc. is the larger business by last-quarter revenue ($20.3M vs $18.7M, roughly 1.1× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -32.5%, a 31.7% gap on every dollar of revenue. On growth, CytomX Therapeutics, Inc. posted the faster year-over-year revenue change (-25.7% vs -51.5%). Ispire Technology Inc. produced more free cash flow last quarter ($-4.0M vs $-15.8M). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -17.8%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.
CTMX vs ISPR — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $20.3M |
| Net Profit | $-154.0K | $-6.6M |
| Gross Margin | — | 17.1% |
| Operating Margin | -6.9% | -33.9% |
| Net Margin | -0.8% | -32.5% |
| Revenue YoY | -25.7% | -51.5% |
| Net Profit YoY | 97.6% | 17.4% |
| EPS (diluted) | — | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $20.3M | ||
| Q3 25 | — | $30.4M | ||
| Q2 25 | $18.7M | $20.1M | ||
| Q1 25 | $50.9M | $26.2M | ||
| Q4 24 | $38.1M | $41.8M | ||
| Q3 24 | $33.4M | $39.3M | ||
| Q2 24 | $25.1M | $37.3M | ||
| Q1 24 | $41.5M | $30.0M |
| Q4 25 | — | $-6.6M | ||
| Q3 25 | — | $-3.3M | ||
| Q2 25 | $-154.0K | $-14.8M | ||
| Q1 25 | $23.5M | $-10.9M | ||
| Q4 24 | $18.9M | $-8.0M | ||
| Q3 24 | $5.7M | $-5.6M | ||
| Q2 24 | $-6.5M | $-3.5M | ||
| Q1 24 | $13.8M | $-5.9M |
| Q4 25 | — | 17.1% | ||
| Q3 25 | — | 17.0% | ||
| Q2 25 | — | 12.3% | ||
| Q1 25 | — | 18.2% | ||
| Q4 24 | — | 18.5% | ||
| Q3 24 | — | 19.5% | ||
| Q2 24 | — | 28.3% | ||
| Q1 24 | — | 20.4% |
| Q4 25 | — | -33.9% | ||
| Q3 25 | — | -8.9% | ||
| Q2 25 | -6.9% | -72.7% | ||
| Q1 25 | 44.4% | -40.4% | ||
| Q4 24 | 46.4% | -17.6% | ||
| Q3 24 | 12.3% | -13.4% | ||
| Q2 24 | -33.7% | -9.2% | ||
| Q1 24 | 28.1% | -18.8% |
| Q4 25 | — | -32.5% | ||
| Q3 25 | — | -10.7% | ||
| Q2 25 | -0.8% | -73.4% | ||
| Q1 25 | 46.2% | -41.5% | ||
| Q4 24 | 49.6% | -19.1% | ||
| Q3 24 | 17.2% | -14.2% | ||
| Q2 24 | -26.0% | -9.4% | ||
| Q1 24 | 33.3% | -19.7% |
| Q4 25 | — | $-0.12 | ||
| Q3 25 | — | $-0.06 | ||
| Q2 25 | — | $-0.26 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | — | $-0.07 | ||
| Q1 24 | — | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $17.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $-7.7M |
| Total Assets | $175.1M | $84.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $22.7M | ||
| Q2 25 | $49.0M | $24.4M | ||
| Q1 25 | $47.6M | $23.5M | ||
| Q4 24 | $38.1M | $34.4M | ||
| Q3 24 | $40.6M | $37.7M | ||
| Q2 24 | $43.2M | $35.1M | ||
| Q1 24 | $36.2M | $39.5M |
| Q4 25 | — | $-7.7M | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | $119.9M | $604.7K | ||
| Q1 25 | $25.0M | $14.8M | ||
| Q4 24 | $-456.0K | $24.2M | ||
| Q3 24 | $-23.5M | $30.7M | ||
| Q2 24 | $-31.2M | $34.5M | ||
| Q1 24 | $-31.7M | $35.9M |
| Q4 25 | — | $84.4M | ||
| Q3 25 | — | $96.4M | ||
| Q2 25 | $175.1M | $102.2M | ||
| Q1 25 | $98.5M | $115.7M | ||
| Q4 24 | $120.5M | $132.0M | ||
| Q3 24 | $139.0M | $129.0M | ||
| Q2 24 | $159.2M | $122.6M | ||
| Q1 24 | $184.7M | $108.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-4.0M |
| Free Cash FlowOCF − Capex | $-15.8M | $-4.0M |
| FCF MarginFCF / Revenue | -84.6% | -19.9% |
| Capex IntensityCapex / Revenue | 0.1% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-14.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-4.0M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | $-15.8M | $4.7M | ||
| Q1 25 | $-21.0M | $-12.5M | ||
| Q4 24 | $-19.9M | $-3.2M | ||
| Q3 24 | $-20.7M | $3.6M | ||
| Q2 24 | $-19.5M | $-1.4M | ||
| Q1 24 | $-26.0M | $3.4M |
| Q4 25 | — | $-4.0M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | $-15.8M | $3.7M | ||
| Q1 25 | $-21.2M | $-12.7M | ||
| Q4 24 | $-20.0M | $-3.2M | ||
| Q3 24 | $-20.7M | $3.3M | ||
| Q2 24 | $-19.6M | $-2.2M | ||
| Q1 24 | $-26.2M | $3.3M |
| Q4 25 | — | -19.9% | ||
| Q3 25 | — | -3.9% | ||
| Q2 25 | -84.6% | 18.6% | ||
| Q1 25 | -41.6% | -48.4% | ||
| Q4 24 | -52.5% | -7.7% | ||
| Q3 24 | -62.1% | 8.5% | ||
| Q2 24 | -78.2% | -5.9% | ||
| Q1 24 | -63.1% | 10.9% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.1% | 4.8% | ||
| Q1 25 | 0.2% | 0.7% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | 0.4% | 2.0% | ||
| Q1 24 | 0.3% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
ISPR
Segment breakdown not available.
